2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Pathology, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

5473 Open-label multicenter feasibility study of elranatamab utilized in newly diagnosed plasmablastic lymphoma with or without HIV in consolidation after definitive therapy; The epic study

Michael Buege, PharmD, Zhengjia Chen, PhD2, Carlos Galvez, MD3, Ana Maria Avila Rodriguez, MD4, Eli P. Darnell5, Juhi A. Gor, MD6, Proskuriakova Ekaterina7, Kyeongmin Kim, PharmD, PhD8, Karen Sweiss, PharmD9, Amy Chadburn, M.D.10, Justin Kline, MD11, Paul Rubinstein, MD12
1 University of Illinois, Chicago, Illinois, United States
2 University of Illinois, Chicago, Illinois, United States
3 University of Illinois, Chicago, Illinois, United States
4 University of Illinois, Chicago, Illinois, United States
5 University of Chicago, Chicago, Illinois, United States
6 University of Illinois, Chicago, Illinois, United States
7 University of Illinois, Chicago, Illinois, United States
8 University of Illinois, Chicago, Illinois, United States
9 University of Illinois, Chicago, Illinois, United States
10 Weill Cornell Medicine, New York, Illinois, United States
11 University of Chicago, Chicago, Illinois, United States
12 University of Illinois, Chicago, Illinois, United States

Introduction and Rationale

Plasmablastic lymphoma (PBL) is a rare, highly aggressive subtype of large B-cell lymphoma characterized by plasmacytoid morphology, loss of mature B-cell markers, with expression of plasma cell antigens CD38, CD138, and MUM1/IRF4. Initially described in persons with HIV  (PWH), PBL is now recognized in both HIV-positive and negative individuals.

Despite multi-agent chemotherapy, including dose-adjusted EPOCH, and recent attempts to incorporate novel agents (e.g., daratumumab), survival remains poor, with approximately 50% of patients progressing in 2 years. At first relapse, PBL is hard to salvage, with a median survival of only 0.6 years, highlighting the need for more effective upfront therapeutic strategies (Hamby et al. Blood Cancer J. 2026). The homogeneous expression of B-cell maturation antigen (BCMA) in PBL provides a compelling therapeutic target. Elranatamab (Elra) is a BCMA-directed bispecific T-cell engager approved for relapsed/refractory multiple myeloma. It demonstrated potent anti-tumor activity and manageable toxicity with subcutaneous administration. Case reports suggest that BCMA-directed T-cell engagers can induce remissions in relapsed PBL as a single agent. We hypothesized that administering Elra as consolidation for PBL after definitive chemotherapy offers the potential to deepen responses by clearing residual disease, improving survival, while mitigating the risk of immune effector cell-associated neurotoxicity syndrome (ICANS) and cytokine release syndrome (CRS) associated with high tumor volume. This hypothesis forms the rationale for the EPIC study (NCT07647432). Methods: The EPIC study is an investigator-initiated, prospective, multicenter, single-arm feasibility study evaluating Elra consolidation following definitive frontline chemotherapy in patients with PBL.  Eligible patients are ≥18 years of age with histologically confirmed stage II–IV PBL or stage I disease with elevated lactate dehydrogenase or bulky disease, irrespective of HIV status, who achieve a complete response (CR) or partial response (PR) following frontline therapy. PWH will be required to have CD4+ T-cell count ≥50 cells/ml to enroll. Elra is administered subcutaneously for six 28-day cycles using the approved step-up dosing schedule (12 mg, 32 mg, and 76 mg), followed by weekly dosing through Cycle 1, and every 2 to 4 week dosing subsequently based on protocol specified time points for a completion of 6 cycles in total. Disease assessments are performed by PET/CT after Cycle 3, at the end of treatment, and every 6 months thereafter for up to 2 years. Seventeen patients will be enrolled across participating sites. Statistics: The primary endpoint is feasibility, defined as at least 65% of patients completing three cycles of Elra consolidation.  Assuming a true feasibility rate of 80%, enrollment of 17 patients provides 80% power at a one-sided α = 0.05 to demonstrate feasibility if at least 11 of 17 patients successfully complete three cycles. Early stopping rule for ≥ 3 patients developing G3/4 ICANS or CRS has been established. Key secondary endpoints include CR rates for patients completing 6 cycles of consolidation, safety and tolerability including the incidence, severity, and management of CRS and ICANS, event-free survival, progression-free survival, and overall survival at 1- and 2-year post-Elra consolidation, quality of life measures during and after consolidation, and the conversion rate from PR to CR at the end of Cycle 3 and Cycle 6. We will also assess the effects of Elra on CD4 T-cell counts and HIV-1 viral load in PWH. Key Exploratory objectives include the characterization of Elra pharmacokinetics, changes in circulating tumor DNA and serum BCMA, and expression of BCMA by immunohistochemistry and their correlation with clinical outcomes.

Michael Buege, PharmD: No relevant conflicts of interest to declare.